Glaukos Corporation (NYSE:GKOS) Q4 2023 Earnings Conference Call February 21, 2024 4:30 PM ET
Company Participants
Chris Lewis - Vice President of Investor Relations & Corporate Affairs
Thomas W. Burns - Chairman and Chief Executive Officer
Joseph E. Gilliam - President and Chief Operating Officer
Alex R. Thurman - Chief Financial Officer
Conference Call Participants
Tom Stephan - Stifel
Ryan Zimmerman - BTIG
Larry Biegelsen - Wells Fargo
Matthew O'Brien - Piper Sandler
Margaret Kaczor - William Blair
Allen Gong - JPMorgan
Joanne Wuensch - Citi
David Saxon - Needham and Company
Sam Brodovsky - Truist Securities
Operator
Welcome to the Glaukos Corporation’s Fourth Quarter and Full Year 2023 Financial Results Conference Call.
Copies of the company's press release and quarterly summary document, both issued after the market closed today, are available at www.glaukos.com. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] This call is being recorded, and an archived replay will be available online in the Investor Relations section at www.glaukos.com.
I will now turn the call over to Chris Lewis, Vice President of Investor Relations and Corporate Affairs. Please go ahead.
Chris Lewis
Thank you and good afternoon. Joining me today are Glaukos’ Chairman and CEO, Tom Burns; President and COO, Joe Gilliam; and CFO, Alex Thurman.
Similar to prior quarters, the company has posted a document on its investor relations website under the financials and filings quarterly results section titled quarterly summary. This document is designed to provide the investment community with a summarized and easily accessible reference document that details the key facts associated with the quarter, the state of the company’s business objectives and strategies, any forward statements or guidance we may make. This document is designed to be read by investors before the regularly scheduled quarterly conference call.
As such, for this call, we will make brief prepared remarks and transition into a question-and-answer session. To ensure ample time and opportunity to address everyone’s questions, we request that you limit yourself to one question and one follow-up. If you still have additional questions, you may get back into the queue.
Please note that all statements other than statements of historical facts made on this call that address activities, events or developments we expect, believe, or anticipate will or may occur in the future are forward-looking statements. These include statements about our plans, objectives, strategies and prospects regarding, among other things, our sales, products, pipeline technologies and clinical trials, U.S. and international commercialization, market development efforts, the efficacy of our current and future products, competitive market position, regulatory strategies and reimbursement for our products, financial condition and results of operations as well as the expected impact of general macroeconomic conditions including foreign currency fluctuations on our business and operations.